Ero Copper Corp (ERO)vsVertex Pharmaceuticals Inc (VRTX)
ERO
Ero Copper Corp
$28.48
+5.09%
BASIC MATERIALS · Cap: $2.83B
VRTX
Vertex Pharmaceuticals Inc
$429.82
+1.13%
HEALTHCARE · Cap: $107.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1222% more annual revenue ($12.22B vs $923.93M). VRTX leads profitability with a 35.5% profit margin vs 31.6%. ERO trades at a lower P/E of 9.7x. ERO earns a higher WallStSmart Score of 78/100 (B+).
ERO
Strong Buy78
out of 100
Grade: B+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+7.2%
Fair Value
$33.93
Current Price
$28.48
$5.45 discount
Margin of Safety
+57.2%
Fair Value
$992.87
Current Price
$429.82
$563.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 33 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 34.7%
Revenue surging 110.4% year-over-year
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 24 in profit
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ERO
The strongest argument for ERO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 31.6% and operating margin at 34.7%. Revenue growth of 110.4% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ERO
No major red flags identified for ERO, but monitor valuation.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ERO profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
ERO carries more volatility with a beta of 1.56 — expect wider price swings.
ERO is growing revenue faster at 110.4% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
ERO scores higher overall (78/100 vs 66/100), backed by strong 31.6% margins and 110.4% revenue growth. VRTX offers better value entry with a 57.2% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ero Copper Corp
BASIC MATERIALS · COPPER · USA
Ero Copper Corp. The company is headquartered in Vancouver, Canada.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other COPPER Stocks
Want to dig deeper into these stocks?